Kailera Therapeutics has launched into the increasingly crowded obesity space with a portfolio of assets acquired from China ...

Shattuck Labs has hammered another nail into the coffin of CD47. After seeing a “modest” effect on survival in blood cancer, ...

IGM Biosciences ended last year laying off staff and streamlining its cancer pipeline. | IGM Biosciences ended last year ...

Antibiotics are one of the most common medicines in the world, with about 236 million prescriptions in the U.S. | The company ...

With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its ...

Remedee Labs, a startup based in Paris, France, has received a European approval for its device-based approach to treating ...

Rivus already announced in August that the trial hit its key endpoint, but today fleshed out that win with some figures.

After a six-month beta testing period, the European Clinical Trials Information Network is rolling out its patient ...

A large trial of people with earlier stages of prostate cancer compared two types of external radiation treatments ...

Kezar Life Sciences went all in on its autoimmune candidate zetomipzomib after a restructuring last year. | The voluntary ...

A bipolar disorder research initiative backed by Big Tech has announced $36 million in new funding for research into the ...

Cereno Scientific’s hypertension drug was shown to improve the risk score of 43% of patients in a phase 2 study.